Elevation Partners offloads 21.5 lakh shares in Ixigo parent for Rs 38.3 crore
Elevation Capital
(formerly Saif Partners India) has sold 21.5 lakh shares in
Le Travenues Technology
, the parent company of
online travel aggregator
Ixigo, for Rs 38.27 crore (around $4.5 million).
According to disclosures filed with the BSE on Monday, Elevation sold 21.5 lakh shares at Rs 178 each. It continues to hold a 13% stake in the company.
Elevation Capital had invested Rs 63.1 crore in Ixigo through various tranches. As of the quarter ending March 31, Elevation had around a 14% stake in the company, holding 5.46 crore shares.
Prior to this, the early-stage venture capital firm had sold shares worth Rs 100 crore through the
pre-IPO secondary sale
and sold shares worth around Rs 181 crore from the offer for sale (OFS) component of the IPO.
This comes at a time when Ixigo saw its net profit
increase significantly by 128% year-on-year (YoY)
to Rs 16.7 crore for the quarter ended March. The company reported operating revenue of Rs 284 crore for the quarter, up 72% from Rs 165 crore a year ago, on account of growth across all lines of business.
Live Events
Founded in 2007 by Aloke Bajpai and Rajnish Kumar, Ixigo allows users to book train, flight, and bus tickets while offering various utility tools and services such as train PNR status and confirmation predictions and updates for train seat availability.
Discover the stories of your interest
Blockchain
5 Stories
Cyber-safety
7 Stories
Fintech
9 Stories
E-comm
9 Stories
ML
8 Stories
Edtech
6 Stories
It also provides personalised recommendations and automated customer support. According to the company, it has 544 million annual active users with 83 million monthly active users.
Ixigo was listed on the exchanges on June 18 last year at Rs 138, a premium of 48.5% over its issue price of Rs 93. It closed on Monday at Rs 174.60 on the BSE.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
35 minutes ago
- Time of India
Jewellery startup True Diamond raises Rs 26 crore in pre-Series A funding round
New Delhi: Lab-grown diamond jewellery brand True Diamond has raised Rs 26 crore in a pre-Series A funding round led by India Quotient , with participation from existing backers Titan Capital Winners Fund and Huddle Ventures, as it sets its sights on aggressive offline expansion, according to a media release on Wednesday. The company plans to use the capital to accelerate its omnichannel strategy, with a specific focus on offline growth. It has already opened retail outlets in Mumbai, Hyderabad, and Noida, and intends to expand across metro cities to offer immersive brand experiences. Parin Shah , Co-founder of True Diamond said, 'We're building a next-gen brand experience through high-quality lab-grown diamonds , cutting-edge content, and a retail journey that breaks away from the conventional. This round gives us the ability to scale this vision faster.' Founded in early 2024 by Darayus Mehta and Parin Shah, the Mumbai-based startup aims to modernize the jewellery experience for Indian consumers through high-quality lab-grown diamonds, design innovation, and a differentiated brand journey.
Time of India
35 minutes ago
- Time of India
Gold prices seen to face a big crash in just two months
Gold prices may have hit their peak and could decline by 12–15 per cent in dollar terms over the next two months, according to Quant Mutual Fund. 'However, our medium-term and long-term views are equally constructive and we reiterate that a meaningful percentage of your portfolio should be dedicated towards precious metals,' it added. A US-based Morningstar analyst has already forecasted a 38 per cent drop in the next few years. On Tuesday, retail gold prices hovered around Rs 96,960 per 10 gm. With a 3 per cent goods and services tax, the price of 10 gm of gold stood at Rs 99,868. Kavita Chacko, research head of India at World Gold Council, said stability in prices could prompt a resurgence in demand in the world's second-largest consumer of the yellow metal. The rise in gold prices is hurting retailers. Gold jewellery sales in India fell 30 per cent to 1,600 kg on average in the past fortnight, according to the India Bullion & Jewellers Association (IBJA), as prices shot up nearly 5 per cent . 'In the first fortnight of May, which was followed by Akshaya Tritiya, there was some momentum as prices started falling, touching Rs 92,365 per 10 gm on May 15. But since then, the price of the yellow metal has again started to move northwards, which has dampened the demand,' said Surendra Mehta, national secretary, IBJA. Gold's recent rally was fueled by economic uncertainty, inflation concerns, and geopolitical tensions. Investors turned to gold as a safe asset, particularly amid ongoing trade disputes initiated during former US President Donald Trump's tenure. However, multiple factors could now drive prices downward. US trade tensions influencing gold markets Trade tensions between the United States and China are keeping investors on edge. Market participants are now watching closely for a possible call this week between President Donald Trump and Chinese President Xi Jinping. This comes just days after Trump accused China of violating an agreement to reduce tariffs and trade barriers. In Europe, the European Commission has pushed back, stating it will urge the U.S. to lower or eliminate tariffs. However, the U.S. is still moving ahead with plans to double steel and aluminum tariffs to 50 per cent . According to a draft letter seen by Reuters, Washington is also pressing countries to submit revised trade offers by Wednesday to speed up negotiations before a five-week deadline.
The Hindu
44 minutes ago
- The Hindu
Gland Pharma gets U.S. FDA nod for Angiotensin II Acetate Injection
Generic injectable focused Gland Pharma's version of La Jolla Pharma's Giapreza injection for increasing blood pressure in adults with septic or other distributive shock has received U.S. Food and Drug Administration approval. It is the exclusive first-to-file and consequently eligible for 180 days of generic drug exclusivity, Gland Pharma said on Wednesday, announcing U.S. FDA approval for its abbreviated new drug application related to Angiotensin II Acetate Injection 2.5 mg/mL. Bioequivalent and therapeutically equivalent to reference listed drug Giapreza of La Jolla Pharma LLC, the product had U.S. sales of around $58 million for the 12 months ended March 2025, Gland Pharma said citing IQVIA numbers. The company's shares closed 1.88% higher at ₹1,623.70 apiece on the BSE.
